Zarogoulidis Konstantinos, Zarogoulidis Paul, Darwiche Kaid, Boutsikou Efimia, Machairiotis Nikolaos, Tsakiridis Kosmas, Katsikogiannis Nikolaos, Kougioumtzi Ioanna, Karapantzos Ilias, Huang Haidong, Spyratos Dionysios
Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
J Thorac Dis. 2013 Sep;5 Suppl 4(Suppl 4):S389-96. doi: 10.3978/j.issn.2072-1439.2013.07.10.
Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug.
根治性手术是适合的Ⅰ期非小细胞肺癌（NSCLC）患者的标准治疗方法。辅助治疗仅应作为研究试验的一部分提供。Ⅱ期和ⅢA期以顺铂为基础的辅助化疗仍然是完全切除的NSCLC肿瘤的金标准。此外，N2淋巴结阳性患者应接受放疗。对于晚期ⅢB/Ⅳ期或无法手术的NSCLC患者，应提供多学科治疗，包括4个周期的以顺铂为基础的化疗加第三代细胞毒性药物或细胞生长抑制剂（抗EGFR、抗VEGFR）药物。
